TY - JOUR T1 - 欧洲呼吸杂志JO - - 欧洲呼吸j执行 - 10.1183 / 13993003.01697-2019 VL - 55 - 2 SP - 1901697 AU - 穆德，熔块I. AU - 迪在癌症患者JF附带静脉血栓栓塞的临床意义Nisio, Marcello AU - Ay, Cihan AU - Carrier, Marc AU - Bosch, Floris T.M. AU - Segers, Annelise AU - Kraaijpoel, Noémie AU - Grosso, Michael A. AU - Zhang, George AU - Verhamme, Peter AU - Wang, Tzu-Fei AU - Weitz, Jeffrey I. AU - Middeldorp, Saskia AU - Raskob, Gary AU - Beenen, Ludo F.M. AU - Büller, Harry R. AU - van Es, Nick Y1 - 2020/02/01 UR - //www.qdcxjkg.com/content/55/2/1901697.abstract N2 - Introduction In cancer patients, current guidance suggests similar treatment for incidental and symptomatic venous thromboembolism (VTE), mainly based on retrospective data. We aimed to evaluate anticoagulant therapy in cancer patients with incidental and symptomatic VTE.Methods The Hokusai VTE Cancer Study was a randomised controlled trial comparing edoxaban with dalteparin for cancer-associated VTE. The primary outcome was the composite of first recurrent VTE or major bleeding. Secondary outcomes included major bleeding, recurrent VTE and mortality. Outcomes in patients with incidental and symptomatic VTE were evaluated during the 12-month study period.Results 331 patients with incidental VTE and 679 patients with symptomatic VTE were enrolled, of whom the index event was confirmed by an independent radiologist. Median durations of anticoagulant treatment were 195 and 189 days, respectively. In patients with incidental VTE, the primary outcome occurred in 12.7% of patients, major bleeding in 6.6% of patients and recurrent VTE in 7.9% of patients. Out of the 26 VTE recurrences in patients with incidental VTE, five (31%) were incidental, seven (44%) were symptomatic and four (25%) were deaths for which pulmonary embolism could not be ruled out. In patients with symptomatic VTE, the primary outcome occurred in 13.8% of patients, major bleeding in 4.9% of patients and recurrent VTE in 10.9% of patients. All-cause mortality was similar in both groups.Conclusion Clinical adverse outcomes are substantial in both cancer patients with incidental and symptomatic VTE, supporting current guideline recommendations that suggest treating incidental VTE in the same manner as symptomatic VTE.In cancer patients with incidental venous thromboembolism (VTE), the risk of recurrent VTE is substantial despite initiation of anticoagulant treatment. Incidental VTE is a serious condition, which should be treated similar to symptomatic VTE. http://bit.ly/2qM4XUp ER -